China
Africa
Explore chapters and articles related to this topic
Sedative and Hypnotic Drugs
Published in Sahab Uddin, Rashid Mamunur, Advances in Neuropharmacology, 2020
Arup Kumar Misra, Pramod Kumar Sharma
Filorexant (MK-6096) a promising agent acting antagonist at orexin receptor for the treatment of sleep disorders. It acts on OX-1 and OX-2 receptors as a dual antagonist. It improves the sleep pattern of the patient as it induces sleep and decreases locomotor activity. It was not developed beyond Phase II clinical trials which might be due to the cost in its drug development or due to its unwanted side effects (Kathryn et al., 2017).
Emerging drugs for the prevention of migraine
Published in Expert Opinion on Emerging Drugs, 2021
Oyindamola Ogunlaja, Nazia Karsan, Peter Goadsby
In a randomized, double blind, placebo-controlled trial – filorexant, a dual orexin receptor antagonist was tested in patients [77]. Patients experiencing 4–14 migraine days a month during a one-month baseline period were randomized to receive filorexant 10 mg nightly or placebo for 3 months. One hundred and twenty patients were treated with filorexant and 115 with placebo. Efficacy was assessed by mean monthly migraine days (which they defined as headache + at least one associated migraine symptom) and headache days. There was no statistically significant difference between the treatment and the placebo group for change from baseline in mean monthly migraine or headache days.
Recently approved and emerging drug options for migraine prophylaxis
Published in Expert Opinion on Pharmacotherapy, 2022
Enrico Bentivegna, Michelangelo Luciani, Valeria Ferrari, Silvia Galastri, Francesco Baldari, Francesco Scarso, Piera A. Lamberti, Paolo Martelletti
Orexin and its receptors are other elements involved in neurotransmission at the level of the trigeminovascular system and in migraine pathogenesis [111,112]. Nevertheless, filorexant, a new molecule that acts as an orexin receptor antagonist, showed no significant therapeutic effects in the treatment of migraine [113]. It is possible that molecules with more selective action against this receptor may give better results.